Low-Density Lipoprotein Cholesterol Reduction and Prevention of Cardiovascular Disease

Por Stein, Evan A.
Publicado em 2009

What matters most in pediatric familial hypercholesterolemia, genotype or phenotype?(1)

Por Raal, Frederick J., Stein, Evan A.
Publicado em 2014

Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial

Por Stein, Evan A., Roth, Eli M., Rhyne, James M., Burgess, Tracy, Kallend, David, Robinson, Jennifer G.
Publicado em 2010

Effects of Intensive Atorvastatin and Rosuvastatin Treatment on Apolipoprotein B-48 and Remnant Lipoprotein Cholesterol Levels

Por Otokozawa, Seiko, Ai, Masumi, Van Himbergen, Thomas, Asztalos, Bela F., Tanaka, Akira, Stein, Evan A., Jones, Peter H., Schaefer, Ernst J.
Publicado no Atherosclerosis (2008)

Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers

Por van Himbergen, Thomas M., Matthan, Nirupa R., Resteghini, Nancy A., Otokozawa, Seiko, Ai, Masumi, Stein, Evan A., Jones, Peter H., Schaefer, Ernst J.
Publicado em 2009

Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial

Por Fayad, Zahi A, Mani, Venkatesh, Woodward, Mark, Kallend, David, Abt, Markus, Burgess, Tracy, Fuster, Valentin, Ballantyne, Christie M, Stein, Evan A, Tardif, Jean-Claude, Rudd, James H F, Farkouh, Michael E, Tawakol, Ahmed
Publicado em 2011

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role

Por Raal, Frederick J., Giugliano, Robert P., Sabatine, Marc S., Koren, Michael J., Blom, Dirk, Seidah, Nabil G., Honarpour, Narimon, Lira, Armando, Xue, Allen, Chiruvolu, Padmaja, Jackson, Simon, Di, Mei, Peach, Matthew, Somaratne, Ransi, Wasserman, Scott M., Scott, Rob, Stein, Evan A.
Publicado no J Lipid Res (2016)